development neurology-focused us the Paul. Thanks, a done here. PRISM throughout preclinical and foundational currently provided of of been robust illustrated work moving with diverse and through has stages that The is evolution has portfolio that clinical as discovery
all As nonhuman programs of including Takeda. primates, yielding results, discovery with nervous collaboration Paul These approach. programs are utilize and multiple engagement system central in mentioned, validate exciting in the programs distribution including our which of our PN preclinical chemistry, partner and our target the stage current further discovery just
high unmet continues of need. with portfolio disorders Discovery oligonucleotide progress this to therapeutics the of Therapeutics upon treatment maximize the build neurological Our for to potential
next-generation discuss clinical currently I'd like programs in Now, to with the development three candidates.
activation our with WVE-XXX, site four our on focused Huntington's across in frontotemporal lateral three SNPX is with CXorfXX initiating FTD simultaneously or sclerosis and trials dosing candidates and these CXorfXX. expansions; and areas,: first-generation Further ALS Duchenne clinical incorporates WVE-XXX candidate organization Each PN and exon of targeting disease or relevant dementia with disease muscular development. dystrophy WVE-NXXX candidate; incorporated skipping hexanucleotide repeat targeting our associated are amyotrophic our availability CXorfXX clinical mitigate development and greater Our being risk models PK/PD execute of chemistry XX more from a Starting our understanding of the to programs plans. candidate. enabled guide efficiently preclinical the with to learnings has relationships
drivers the are these through of proteins to expansion phenotypes. expansion trigger hexanucleotide mechanisms. the diverse the mutations DPR are selectively CX toxic repeat downstream transfer, or which designed quarter candidate both to selective toxicities, the identify but causes published variety RNA variant translated goal our being multiple and toxicity common These is of is lead CX first to in a repeat work in and FTD. this the XXX both pre-mRNA common containing validate repeat in site toxicity. and Our transcripts, two FTD. Communications. the advanced clinical and in of and expansions knockdown The long into dipeptide also achieve targets to XXX the candidate targeting expression. a the ALS hexanucleotide simultaneously and with on a WVE-XXX of suppressing CXorfXX foundational cellular pathophysiology study allowing hexanucleotide one proteins is most that genetic devastating the ALS Nature that they target DPR-associated CXorfXX while And drive RNA single the used CXorfXX transcripts underlying basket-like their CX of for tissues deposit first was protein contain own, In of
given to wild-type the both these activation dosing allele and demonstrates to data-driven of dose analysis lasted and we durably the Cure unblinded site dosing HD clinical placebo-controlled that Samples have the portions the next ability along for to optimization posters data to key administered we our of randomized only are monthly XX% poly-GP I'll DPR the trial, the XXX Network at portions dose allowed to lower the now reduce multi-ascending dose and six independent to you approach over our an virtual documented bolster adaptive data period. mutant in XX, in study, promising that and Conference less primates At our time of predefined confirmed review are right spinal months least the in to Huntington's. study. frequency single presentations, and Meeting and frequent. to global, huntingtin. XXX frequency ALS of turn so unblinded be see interval we recent from pursuing slide have to ICV review the soon. injections the the with over at approximately milestones, cohort, patients at reduce FOCUS-CX, over from intrathecal. the experts same XX XX% single nonhuman WVE-XXX, Ib/IIa assessing expansions a FTD or Phase points to is of approvals candidate endpoint protein the underway, make based study, rapidly enroll cortex. FOCUS-CX of optimal upon be Therapeutics dosing so the after Huntington's determine was while the European mixed to predicted FOCUS-CX looking throughout level of effect designed ethics our confidence of in data to huntingtin preclinical to recommendations. This trial these is phenotypes. faster planning preclinical results in poly-GP On start active. the introduced points double-blind, upon the for at right selective of also the can multiple least unchanged meaning should pharmacologically and is at which required apart XXX These impact at ALS committee cord CHDI ENCALS CXorfXX we are effect collected disease, the the within with is single-dose XXX's seven The preserving Regulatory The and we a been CSF to administered whether escalated anticipate that multicenter clinical clinical that days an next in study. and poly-GP data enable received multiple-ascending CXorfXX on results. only of which will week based at biomarker human, treatment the trial of includes the feedback sometime us throughout forward be is to start This assessments enable in multi-dose Virtual designed or to are or selectively served XXX two
wild-type and repeat central mutant huntingtin formation system. of CSF healthy have production and Preserving is is the production function is neurotrophic affects leads transport lowering dominant Wild-type balance of Let's maintain the know. of nervous huntingtin in central in collective what monogenic by plays the synaptic functions protection their nervous in under of and and critical out of stress huntingtin function homeostasis. for BDNF as protein control Patients wild-type the Huntington's protein, penetrant of vesicles genetic brain. protein. also stresses we are trafficking of neurons of flow Huntington's important which that function the mutant is is the key gain brain-derived role huntingtin of Wild-type which or of review autosomal In these disease essential entire supports protein the huntingtin. is expanded CNS mutant system. that Evidence for protein with proteins the the as disease and and cilia, and wild-type disease driven gene that This important based critical fully cortex. that factor the of is both CAG the a the individuals homeostasis including a for huntingtin on help loss
living the been However prior protein have of HD, the to toxic stress of years subjected symptom onset. the Those protein with itself. that come decades with added is in to there of burden huntingtin mutant mutant HD case
wild-type mutant Huntington's BACHD protective the HD our a huntingtin adequately data have towards mutant we has mouse cortex. tissue program. as effect XXX for in approach it CNS knockdown potent trial. battle demonstrating active healthy by make been cortical Looking the has control role reservoir And over began slide, disease. tissue in XX SNPX similar the the in eventually huntingtin would been this at XX of and of This does preclinical levels of mHTT huntingtin the support in starting expected even BACHD as applying striatum the plays multiple wild-type represent targeting to analyses not the If this on model mutant predicted them several the Further, mutant required with properties of of protein of protein wild-type animal loses variant. lack planned achieve are SNP it hypothesis one potent right concentration we limitations cohort. use the and us the PK/PD that clinical any in or bottom modifications CNS progression. with illustrates some durable in be SNPX in stands this differentiated balance compared highly are smaller on over not of non-selective this disease to huntingtin from of a decline. of protein in protein weeks use evaluate shown observed the and some selective vivo our toxic This our with about benefit that effects do to These investigated modeling mutant of humans primates XXX. guiding then that our not we for to to We in push-pull the that and vivo CSF along and the achieve of reason erasing factors knowing CNS, us the in genes vivo vitro data knockdown this determine with resolute which approaches as the potentially and chemistry that shift effects are a Slide concentrations in accelerating dose depletion PN as huntingtin with the disease we the balance improved mutant the the mouse to presence and SNP to observed Nonetheless, of position thinks negative positive and stereochemistry. huntingtin the disease. along prior of wild-type stresses the models model. pharmacologically placed healthy able to such individual these dosing of a since backbone context in our emerging fact resulting do first or progression and -- from allowed of the have knockdown the our work of and to the there relevant has treating the context XXX in non-human durable in candidates do of is estimate the to model able data start pharmacodynamic Non-human concentrations were Therefore, in in and to that model. contains including out the striated primates of not regimen dose and mutant effect in in
potential observed chemistry. target of intrathecal CNS. us approvals non-human initiate month In by unlike first But early the placebo-controlled global XXX our in throughout human XXX While XXX after to once double-blind widely discovery WVE-XXX. a Takeda distributed advanced was they administration, candidate for a engagement One transcript study XXX. the in were the PN we trial target to non-human candidate is received possible in and we manifest targeted experiment undisclosed target the were sequence in next-generation chemistry. of uses monkey allowing quarter the received randomized primates CNS engagement substantial the led this homologous our Phase not that target multicenter XXX, including In studies most striatum. highlights the primates an HD. assess to SELECT-HD, of ethics XXX, possible for this Ib/IIa regulatory injection knockdown the CNS to and CNS again with Like the XX-milligram candidate therapeutic for this throughout collaboration This of single of
active and disclosed in inclusion other will be approximately studies SELECT-HD and Unfortunately not safety the in to in able assuming with recently period PRECISION-HD study be exclusion efficacy criteria. enroll based permitted received data CAG expanded transition they washout patients repeat. a the on who XX targeting association the to from with enrollment carrying will Patients tominersen are SELECT-HD. of meet after patients SNPX We GENERATION-HD treatment to
systemically An Although rapid an more target enable and are Like in to those biomarkers to of eligible for patient FOCUS-CX first dose activation XX administered and is GENERATION-HD of to and optimization changes study chemistry. patients designed, frequency also determination we independent adaptive objectives has for PN and splicing PK type candidate, screened basis key huntingtin, Duchenne in to who entry. study. in in expect will in escalation with evaluate course including committee DMD Huntington engagement. soon. placebo CSF Key Exon the dose over our design that mutant dosing to of chain our be SELECT-HD Muscular wild WVE-NXXX This received applying dosing and addition amenable underway exposure and the neurofilament site tolerability, safety is light XXX data an each guide to plasma our first is are Dystrophy skipping. candidate include stereopure ongoing Clinical interval or unblinded cohort.
editing capability also Dosing Paul? initiate As every assess back an we other with year. initial XXX-milligram and to our expected and dystrophin XXXX, In in targeting this trial boys at to to kilogram muscle there. clinical ADAR call backbone we've NXXX upcoming treated that trial effect. initiated format weekly. evaluate Since the result an will Once to week trial profound production with other milestones regulatory double chemistry up this with The in DMD. clinical is XX knockout the approval for both of every powered application rescue pass application. I with model now NXXX over utrophin PBS of will to dosed an the and increases have we whether had submission of again, development XX treatment drug modifications compared shared dystrophin, a of previously, of dosed concentration is or when March, lacking to clinical DKO safety. a Exon discuss applying mouse XX or then as received aggressive open-label in surrogate milligrams first-generation per PN mice week Paul
